// //
Skip to Content | Accesskey Details
Bringout the Health Within

New Oscillococcinum® 30 Dose Offers Convenience and Savings to Support Better Wellness

Newtown Square, Pa., Spring 2012—To encourage treatment at the right time, Oscillococcinum is now available in a convenient and economically valuable 30-dose package. Busy parents and professionals alike can better prepare to nip flu-like symptoms in the bud for less, especially in highly contagious environments like homes and offices.

In France, where Oscillococcinum has been well-known as a first-defense medicine for more than 65 years, an online study of 1,200 people showed that one third of users purchase five or more boxes of the traditional 6 dose (a total of 30 doses) per year. Heaviest use spanned seven months—from September to March.1 When initially feeling hot and fatigued, with a headache, body aches and pains, the French know to act quickly with this familiar homeopathic medicine. They know there’s no need to delay treatment out of concern for side effects, including drowsiness, or interactions with other medications.

Now, to promote preparedness at the crucial early stage, Boiron has cost-effectively packaged its best seller. Within the box, handy break-away 3-dose packs support stocking Oscillo® in purses, at work, in toiletry travel totes and elsewhere to take quick action at the first sign of symptoms.

While having an ample supply removes barriers to treatment due to accessibility, the low cost per dose removes possible price-based hesitations to usage. The 30-dose package cuts cost per dose in half to one dollar per dose. To counter flu-like symptoms that reoccur and spread quickly through the household, there is a possibility that all members of a family of four can be treated at just the right time all winter long for under .1

Oscillococcinum has helped busy folks in 80 countries who can’t afford to be sick get back to what’s important to them. Clinical studies show that, unlike other over-the-counter medicines, Oscillo shortens both the severity and duration of flu-like symptoms.2–5 The latest study published in a British scientific journal found that when patients took Oscillo within 24 hours of the onset of symptoms, nearly 63 percent showed “clear improvement” or “complete resolution” within 48 hours.2

In our current economic climate, the 30-dose package helps people remain productive and save money. Busy working moms and elderly who may not have access to shops when necessary will especially find it an attractive package.

Since its introduction in Sept. 2011, Oscillococcinum 30 dose has quickly gained distribution and can be found in the majority of natural product stores. Suggested retail price is .99 for the 30 dose, compared to .99 for the popular 6 dose and .99 for the 12 dose. Consumers can visit Oscillo.com for a coupon or to find the nearest retail store.


  1. IPSOS patient study. June 2010, collected on-line; 1,200 individuals 18 and older and in which families indexed at four members.
  2. Papp R., et al. “Oscillococcinum® in patients with influenza-like syndromes: a placebo-controlled double blind evaluation.” British Homeopathy Journal April 1998, Vol 87, 69–76.
  3. Ferley JP., et al. “A controlled evaluation of a homeopathic preparation in the treatment of influenza-like syndromes.” British Journal of Clinical Pharmacology 1989, 27: 328–335.
  4. Centre de Recherche et de Documentation Technique, University of Marseilles, France, March 1985.
  5. Centre de Recherche et de Documentation Technique, University of Marseilles, France, April 1983.

About Boiron: Boiron, world leader in homeopathic medicines, is a $852 million public company with 3,700 employees and distribution in 59 countries. It is best known for Oscillococcinum®, a top-selling flu medicine, and its Arnicare® line of pain relievers. For more than 80 years, Boiron has been committed to funding scientific research and educating the public and healthcare professionals on homeopathic medicines. As a pharmaceutical company, Boiron maintains the highest standards in manufacturing, complying with U.S. Food and Drug Administration regulations, the Homeopathic Pharmacopoeia of the United States and drug Good Manufacturing Practices.

Published: March, 2012